Published in Clin Pharmacol Ther on March 14, 2007
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52
Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur J Clin Pharmacol (2009) 1.23
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet (2009) 1.17
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population. Malays J Med Sci (2013) 1.16
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics (2009) 1.15
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother (2008) 1.10
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother (2008) 1.08
Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother (2012) 1.04
Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J Infect Dis (2009) 1.03
Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrob Agents Chemother (2011) 1.01
Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf (2012) 0.97
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother (2012) 0.95
African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health (2013) 0.95
Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos (2010) 0.95
Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother (2010) 0.93
Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol (2011) 0.92
In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet (2013) 0.91
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol (2009) 0.91
The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy (2013) 0.89
Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics (2009) 0.83
Can pharmacogenomics improve malaria drug policy? Bull World Health Organ (2011) 0.82
Distribution of human CYP2C8*2 allele in three different African populations. Malar J (2012) 0.81
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics (2013) 0.80
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother (2014) 0.78
Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. Pharmacogenomics J (2016) 0.78
Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pharmacotherapy (2013) 0.77
Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent. Eur J Clin Pharmacol (2010) 0.77
Single-dose pharmacokinetic interaction between artesunate and amodiaquine: assembling the clues for the purported interaction. Eur J Clin Pharmacol (2008) 0.77
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. Br J Clin Pharmacol (2015) 0.76
Pharmacogenomics of antimicrobial agents. Pharmacogenomics (2014) 0.76
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine (2017) 0.75
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLoS One (2017) 0.75
Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J (2014) 0.75
In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane. Pharmacol Res Perspect (2017) 0.75
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol (1995) 7.12
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res (2000) 3.70
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics (1996) 3.02
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Difficulties in the prevention, diagnosis, and treatment of imported malaria. Arch Intern Med (2000) 2.17
Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem (2000) 2.16
Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med (1998) 2.12
Biopsy-induced tricuspid regurgitation after cardiac transplantation. Ann Thorac Surg (1994) 2.07
Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem J (2001) 2.00
The proteases and pathogenicity of parasitic protozoa. Annu Rev Microbiol (1993) 1.96
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther (2012) 1.88
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther (2012) 1.87
Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem (1993) 1.86
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 1.83
Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci U S A (1993) 1.82
Guidelines for credentialing and granting privileges for endoscopic ultrasound. Gastrointest Endosc (2001) 1.81
Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest (1993) 1.79
Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis (2001) 1.75
Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet (2000) 1.68
Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis (1987) 1.65
Surgical management of temporomandibular joint ankylosis in the pediatric population. Plast Reconstr Surg (1993) 1.60
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet (2001) 1.58
Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics (1975) 1.55
Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics (2001) 1.53
Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol (1994) 1.49
Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother (1988) 1.46
The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Trans R Soc Trop Med Hyg (2001) 1.45
Elevations of CK-MB following pulmonary embolism. A manifestation of occult right ventricular infarction. Chest (1992) 1.44
Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum. Antimicrob Agents Chemother (2001) 1.40
Efficacy of angioscopy in determining the effectiveness of intracoronary urokinase and TEC atherectomy thrombus removal from an occluded saphenous vein graft prior to stent implantation. Cathet Cardiovasc Diagn (1995) 1.39
Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg Med Chem (1999) 1.34
Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease falcipain-2. Protein Expr Purif (2001) 1.32
The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther (1995) 1.31
Identification of three stage-specific proteinases of Plasmodium falciparum. J Exp Med (1987) 1.30
Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol (1998) 1.29
Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur J Med Chem (2001) 1.28
Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys (1998) 1.28
Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos (2001) 1.27
Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother (1998) 1.27
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther (2001) 1.26
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol (1999) 1.23
Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther (1997) 1.22
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics (1997) 1.18
Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry (1991) 1.18
Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect Immun (1995) 1.17
Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg (2000) 1.17
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther (2007) 1.16
Separation of pure polychlorinated biphenyl isomers into two types of inducers on the basis of induction of cytochrome P-450 or P-448. Chem Biol Interact (1977) 1.16
One-stage anterior cervical decompression and posterior stabilization. A study of one hundred patients with a minimum of two years of follow-up. J Bone Joint Surg Am (1995) 1.14
Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther (2011) 1.14
Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol (1998) 1.13
Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther (1995) 1.13
Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. Am J Physiol Gastrointest Liver Physiol (2011) 1.12
Cochlear gene delivery through an intact round window membrane in mouse. Hum Gene Ther (2001) 1.12
Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry (2001) 1.11
Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorg Med Chem (1998) 1.10
Splicing defects in the COL3A1 gene: marked preference for 5' (donor) spice-site mutations in patients with exon-skipping mutations and Ehlers-Danlos syndrome type IV. Am J Hum Genet (1997) 1.10
ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther (2007) 1.09
Recombinant falcipain-2 cleaves erythrocyte membrane ankyrin and protein 4.1. Mol Biochem Parasitol (2001) 1.09
Fusion of liposomes containing a novel cationic lipid, N-[2,3-(dioleyloxy)propyl]-N,N,N-trimethylammonium: induction by multivalent anions and asymmetric fusion with acidic phospholipid vesicles. Biochemistry (1989) 1.09
Toothpick impaction with localized sigmoid perforation: successful colonoscopic management. Gastrointest Endosc (1999) 1.09
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther (1996) 1.08
The structure-activity relationships of halogenated biphenyls as enzyme inducers. Ann N Y Acad Sci (1979) 1.08
Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol (1993) 1.08
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics (1999) 1.08
The role of right ventricular systolic dysfunction and elevated intrapericardial pressure in the genesis of low output in experimental right ventricular infarction. Circulation (1982) 1.08
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther (1999) 1.05
Bioresorbable fixation for congenital pediatric craniofacial surgery: a 2-year follow-up. Pediatr Neurosurg (2000) 1.03
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther (1998) 1.03
TRAM flap breast reconstruction and contralateral reduction or mastopexy. Plast Reconstr Surg (1993) 1.03
Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res (1992) 1.02
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis (2009) 1.02
Incidence and angiographic predictors of side branch occlusion following high-pressure intracoronary stenting. Am J Cardiol (1997) 1.02
Experimental hepatic porphyria induced by polychlorinated biphenyls. Toxicol Appl Pharmacol (1974) 1.02
Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio- and stereoselective products. J Pharmacol Exp Ther (2001) 1.01
2,3,7,8-Tetrachlorodibenzofuran in a commercially available 99% pure polychlorinated biphenyl isomer identified as the inducer of hepatic cytochrome P-448 and aryl hydrocarbon hydroxylase in the rat. Drug Metab Dispos (1978) 1.01
Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics (1993) 1.01
Pseudo Sister Mary Joseph's nodule. Am J Gastroenterol (1999) 1.00
Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos (1996) 1.00
Complete hydatidiform mole with a coexistent healthy, viable fetus near term: a case report. J Reprod Med (1996) 0.99
Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol (2000) 0.97
Volume loading improves low cardiac output in experimental right ventricular infarction. J Am Coll Cardiol (1983) 0.97
Toxicological assessment of hexachlorobiphenyl isomers and 2,3,7,8,-tetrachlorodibenzofuran in chicks. II. Effects on drug metabolism and porphyrin accumulation. Toxicol Appl Pharmacol (1976) 0.96
Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. Blood (1996) 0.96
Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J Antimicrob Chemother (1991) 0.96
Differential induction of two 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible forms of cytochrome P-450 in extrahepatic versus hepatic tissues. Mol Pharmacol (1984) 0.96
A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics (1995) 0.96
Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem Pharmacol (1999) 0.95
Costs and outcomes of patients admitted with chest pain and essentially normal electrocardiograms. Clin Cardiol (1998) 0.94
Assessment of denaturing high-performance liquid chromatography (DHPLC) in screening for mutations in connexin 26 (GJB2). Hum Mutat (2001) 0.94
The role of endoscopy in dyspepsia. Gastrointest Endosc (2001) 0.93
Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion. J Am Acad Dermatol (1982) 0.93
Limulus amebocyte lysate test in neonates. Am J Clin Pathol (1976) 0.93